🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are increasing around the world, with data suggesting in excess of 82 million infections each year. Notably increased rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary development in the face of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are particularly alarmed about the surge in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Drugs Gain Authorization

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization represents a huge turning point in the management of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

As per findings released by a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The study enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of developing nations.

Medical professionals directly involved have voiced hope. Having a single-dose, oral treatment like this is described as a "critical tool" for gonorrhoea control. This is considered vital to lessen the impact of the illness for people and to prevent the spread of extremely resistant gonorrhoea around the world.